ALK and non-small cell lung carcinoma: For instance, recommendations suggest better disease management by using a multidisciplinary modality in patients with BM from breast cancer, melanoma, and specific genotypes of non-small cell lung cancer (NSCLC) (e.g., epidermal growth factor receptor (EGFR) gene mutations, translocations in the anaplastic lymphoma kinase (ALK) gene).